Edaravone Dexborneol + Placebo
Phase 2UNKNOWN 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Intracerebral Hemorrhage
Conditions
Intracerebral Hemorrhage
Trial Timeline
Mar 1, 2021 → Sep 1, 2023
NCT ID
NCT04714177About Edaravone Dexborneol + Placebo
Edaravone Dexborneol + Placebo is a phase 2 stage product being developed by Sun Pharmaceutical for Intracerebral Hemorrhage. The current trial status is unknown. This product is registered under clinical trial identifier NCT04714177. Target conditions include Intracerebral Hemorrhage.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04714177 | Phase 2 | UNKNOWN |
Competing Products
6 competing products in Intracerebral Hemorrhage
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| NXY-059 | AstraZeneca | Phase 2 | 52 |
| Recombinant Factor VIIa + Biological/Vaccine: Placebo | Novo Nordisk | Phase 3 | 76 |
| Recombinant Activated Factor VII (rFVIIa) + Placebo | Novo Nordisk | Phase 3 | 76 |
| PF-05230907 | Pfizer | Phase 1 | 32 |
| CN-105 | Tiantan Bio | Phase 2 | 49 |
| Albumin + Placebo | Baxter | Phase 2 | 49 |
Other Products from Sun Pharmaceutical
Ilumya Injectable ProductApproved
85
CequaTM (Cyclosporine 0.09%) ophthalmic solutionApproved
85
Cyclosporine + Artificial tearApproved
85
AmifostineApproved
85
Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapyApproved
85